Tremelimumab MOA (Mechanism of Action of Imjudo)
Tremelimumab is marketed by name, Imjudo. It is a CTLA-4 inhibitor that has been approved for the treatment of unresectable HCC and non-small-cell carcinoma. What is CTLA-4? CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a protein receptor that is expressed on the surface of T-cells (a type of immune cell). It functions as a negative regulator … Read more